The drug was able to reduce weight in ... "Innovent’s Phase II mazdutide study shows diabetes patient weight loss" was originally created and published by Clinical Trials Arena, a GlobalData ...

The drug is also being tested in a mid-stage trial in the US. Innovent is seeking approval for mazdutide as a weight loss treatment in China. The drug’s sales in the country may reach $1.3 ...

Lilly retains the rights to the drug in all other countries ... is also seeking regulatory approval in China for mazdutide in both chronic weight management and glycaemic control in type 2 ...

including weight loss and cardiometabolic benefits, compared to the control drug. Now, Innovent has said it plans to file for NMPA approval of the drug in diabetes "in the near term." "Mazdutide ...

Mazdutide has strong efficacy in weight loss and lowering glucose levels in clinical studies ... Innovent has 11 products in the market, 3 new drug applications under the NMPA review, 4 assets in ...